Daniel A. Barocas, MD, MPH, FACS, discusses adjuvant TKI therapy in patients with renal cell carcinoma at high risk of recurrence following cytoreductive nephrectomy.
Daniel A. Barocas, MD, MPH, FACS
Advertisement
Articles by Daniel A. Barocas, MD, MPH, FACS
Daniel A. Barocas, MD, MPH, FACS, an associate professor in the Department of Urology at Vanderbilt University Medical Center, discusses the Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) trial in localized prostate cancer.
Advertisement
Latest Updated Articles
Dr. Barocas on Adjuvant Sunitinib in Renal Cell CarcinomaJanuary 8th 2020
Dr. Barocas on the CEASAR Trial in Localized Prostate CancerDecember 3rd 2019
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
2
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
3
Bispecific-Based Approaches Highlight Key Multiple Myeloma Data Set to Emerge at EHA 2026
4
HERTHENA-Breast04 Is Set to Delineate the Role of HER3-Targeted Therapy in Advanced HR+ Breast Cancer
5